中药联合西药治疗痰瘀互结型冠心病疗效及安全性Meta分析
|
摘要
目的:评价中药联合西药治疗痰瘀互结型冠心病的疗效及安全性。方法:检索2007年1月—2017年4月中文数据库(CNKI、VIP、CBM、万方数据)及英文数据库(Medline、Cochrane Library)。研究对象为已确诊痰瘀互结型冠心病的患者,干预措施及比较类型为:中药加西药与单用西药比较治疗痰瘀互结型冠心病的随机、对照试验。采用Cochrane协作组织制定的偏倚风险评价标准对纳入研究的文献质量(包括随机化、分配、隐藏、盲法、退出与失访)进行评价,使用Revman 5.2软件对资料进行汇总分析。结果:36个以中文发表的RCTs(共3336个研究对象)被纳入研究。在西药常规治疗的基础上加用中药,可明显改善心绞痛疗效、心电图疗效、中医证候疗效、临床疗效和症状疗效,还可以明显改善血脂水平、血浆同型半胱氨酸水平,并无明显不良反应,安全有效。结论:中药和西药联用较单用西药在治疗痰瘀互结型冠心病方面可能具有优势,但还需进一步开展高质量的试验加以证实。
Objective: To assess the effectiveness and safety of Chinese medicine and western medicine in the treatment of coronary heart disease( CHD) with phlegm-stasis cementation syndrome. Methods: databases in Chinese( CNKI,VIP,CBM,and Wanfang Database) and in English( Medline and Cochrane Library) dating from January 2007 to April 2017 were searched and relevant documents retrieved. Participants were patients confirmed by CHD with phlegm-stasis cementation syndrome. We included randomized clinical trials( RCTs) testing Chinese medicine plus western medicine vs. western medicine. Assessments of methodological quality,including randomization,allocation,concealment,blindness,dropping out,and loss of follow-ups were also conducted according to the Cochrane Handbook for Systematic Review of Interventions. Meta-analysis was performed using Rev Man 5. 2 software provided by Cochrane Collaboration. Results: Thirty-six RCTs( involving 3336 patients) were included. All these studies were published in Chinese. The results of Meta analysis showed that the group treated by Chinese medicine and western medicine could improve the efficacy of angina,electrocardiograph,TCM syndrome curative effect,clinical efficacy and symptom effect. It could also improve the level of blood lipid and homocysteine. The results showed that treatment with Chinese medicine and western medicine were safe and had no obvious side effects. Conclusion: Traditional Chinese medicine combined with western medicine in the treatment of CHD with phlegm-stasis cementation syndrome may have an advantage,which need to be confirmed by launching higher quality clinical trials.
Objective: To assess the effectiveness and safety of Chinese medicine and western medicine in the treatment of coronary heart disease( CHD) with phlegm-stasis cementation syndrome. Methods: databases in Chinese( CNKI,VIP,CBM,and Wanfang Database) and in English( Medline and Cochrane Library) dating from January 2007 to April 2017 were searched and relevant documents retrieved. Participants were patients confirmed by CHD with phlegm-stasis cementation syndrome. We included randomized clinical trials( RCTs) testing Chinese medicine plus western medicine vs. western medicine. Assessments of methodological quality,including randomization,allocation,concealment,blindness,dropping out,and loss of follow-ups were also conducted according to the Cochrane Handbook for Systematic Review of Interventions. Meta-analysis was performed using Rev Man 5. 2 software provided by Cochrane Collaboration. Results: Thirty-six RCTs( involving 3336 patients) were included. All these studies were published in Chinese. The results of Meta analysis showed that the group treated by Chinese medicine and western medicine could improve the efficacy of angina,electrocardiograph,TCM syndrome curative effect,clinical efficacy and symptom effect. It could also improve the level of blood lipid and homocysteine. The results showed that treatment with Chinese medicine and western medicine were safe and had no obvious side effects. Conclusion: Traditional Chinese medicine combined with western medicine in the treatment of CHD with phlegm-stasis cementation syndrome may have an advantage,which need to be confirmed by launching higher quality clinical trials.
引文
[1]曹洪欣,张华敏.痰瘀互结与冠心病发病机理辨识[J].中华中医药学刊,2001,19(6):544-546.
[2]中华人民共和国卫生部.中药新药研究指导原则[M].北京:中国医药科出版社,2002:6-73.
[3]The Cochrane Collaboration.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0(updated March 2011)[S/OL].Editors:Julian PT Higgins and Sally Green.http://www.cochrane.org/.htm.
[4]万洪峰,杨晓卿.泄浊化瘀方治疗痰瘀互结证冠心病的疗效观察[J].大家健康:学术版,2016,10(8):138-139.
[5]任得志,张军茹,申仙利.丹蒌片治疗痰瘀互结型冠心病不稳定型心绞痛的临床观察[J].中西医结合心脑血管病杂志,2014,12(8):1022-1023.
[6]何欣,何立人.瓜蒌薤白养心汤治疗痰瘀互结型冠心病心绞痛临床观察[J].四川中医,2015,33(12):113-116.
[7]刘祖印.通络化痰汤治疗冠心病心绞痛痰瘀互结证的临床分析[J].医学信息,2015,28(46):345.
[8]周占青.薤白通脉汤联合西药治疗冠心病不稳定型心绞痛(痰瘀互结)随机平行对照研究[J].实用中医内科杂志,2015,29(7):110-112.
[9]庞立健,朱凌云,南明花,等.通脉化浊汤治疗痰瘀互结型冠心病心绞痛患者临床疗效评价[J].中华中医药学刊,2013,31(9):1875-1877.
[10]张奎,徐卫东.通络化痰汤治疗冠心病心绞痛痰瘀互结证疗效观察[J].中医药导报,2013,19(12):140-141.
[11]张海文.瓜蒌薤白半夏汤加味治疗冠心病心绞痛痰瘀互结型42例[J].光明中医,2015,30(11):2439-2441.
[12]易慧明.中西医结合治疗痰瘀互结型冠心病稳定型心绞痛的临床分析[J].大家健康旬刊,2014,8(23):93-94.
[13]李防栋,杨学信.心痛灵汤治疗冠心病心绞痛毒热痰瘀互结证疗效观察[J].医药前沿,2015,5(28):330-331.
[14]王宁宁,洛晶,刘超峰.菖琥温胆汤联合β受体阻滞剂治疗冠心病室性早搏(痰瘀互结证)的临床观察[J].现代中医药,2012,32(2):19-20.
[15]王长建,马秀明,王竹风,等.瓜蒌薤白半夏汤合血府逐瘀汤加减治疗痰瘀互结型胸痹心痛32例临床观察[J].新中医,2013(8):12-14.
[16]田丹枫,司国民,彭敏.加味瓜蒌薤白半夏汤治疗冠心病经皮冠状动脉介入术后再发心绞痛痰瘀互结证的临床研究[J].河北中医,2016,38(9):1361-1364.
[17]范虹,安静,刘超峰,等.丹曲方治疗冠心病心绞痛痰瘀毒互结证疗效观察[J].陕西中医,2014(8):973-975.
[18]辜大为.中西医结合治疗阳虚痰瘀互结型冠心病心绞痛49例临床观察[J].中医药导报,2008,14(3):17-18.
[19]周菁,张倩,张焱.白玉参景脉通汤联合常规西药对痰瘀互阻型冠心病患者脂联素水平的影响[J].上海中医药杂志,2016,50(11):42-45.
[20]李淑君,范金茹.柴蒌桃仁汤治疗稳定型心绞痛痰瘀痹阻证的临床研究[J].中医药导报,2010,16(4):19-21.
[21]谭建义.丹蒌片联合西药治疗痰瘀互阻型冠心病心绞痛随机平行对照研究[J].实用中医内科杂志,2013,27(13):20-21.
[22]周敏军.丹蒌片治疗痰瘀互阻型冠心病心绞痛患者70例临床疗效观察[J].中国民族民间医药,2013,22(18):98.
[23]薛振怀,钟伟,程娟.导痰祛瘀汤联合西药治疗痰浊瘀阻型糖尿病合并冠心病随机平行对照研究[J].实用中医内科杂志,2015,29(9):121-123.
[24]谢玉霞,晋卫军,程璐,等.瓜蒌皮注射液联合西药治疗冠心病心绞痛(痰瘀互阻证)合并心衰患者的临床研究[J].实用中西医结合临床,2014,14(7):16-17.
[25]周旭.瓜蒌薤白半夏汤合丹参饮在痰瘀互阻型胸痹治疗中的应用分析[J].中国实用医药,2016,11(29):203-204.
[26]满军.瓜蒌薤白半夏汤合丹参治疗痰阻血瘀型胸痹心痛38例观察[J].中医药临床杂志,2014,26(9):892-893.
[27]王士兵.瓜蒌薤白半夏汤合桃红四物汤联合西药治疗痰阻血瘀型胸痹随机平行对照研究[J].实用中医内科杂志,2016,30(7):52-54.
[28]韩秀芬,韩首章.冠脉通联合西药治疗痰瘀痹阻冠心病心绞痛随机平行对照研究[J].实用中医内科杂志,2016,30(8):66-68.
[29]杨新.冠心通舒汤配合西药治疗痰阻血瘀型胸痹75例[J].实用中医内科杂志,2012,26(1):56-57.
[30]刘宁,姚福梅,李勇,等.化痰祛瘀法对痰浊瘀阻型急性冠脉综合征患者血小板活化功能影响的研究[J].中国实用医药,2010,5(9):9-10.
[31]陈翊,缪灿铭.化痰通络法改善痰瘀阻络型急性冠脉综合征症状及CRP水平[J].光明中医,2008,23(12):1891-1893.
[32]秦玖刚.豁痰通痹汤联合西药治疗痰瘀互阻型胸痹的临床观察[J].中医临床研究,2016,8(20):73-74.
[33]贾秀丽,刘洁,刘华恩.降浊通脉汤治疗痰瘀痹阻型冠心病心绞痛60例[J].河南中医,2007,27(8):28-30.
[34]刘婷,肖振东,李培培.理气化痰祛瘀法治疗冠心病合并高脂血症(痰瘀互阻证)45例[J].中国实验方剂学杂志,2014,20(8):221-225.
[35]杨建波,李鹏,蒋华,等.通瘀化痰法治疗痰瘀互阻证心衰患者的临床研究[J].新疆医科大学学报,2011,34(7):669-673.
[36]杨晓利,周鹏飞,方居正.温胆汤加味联合西药治疗痰瘀痹阻型冠心病30例[J].中医研究,2017,30(2):29-31.
[37]程修平,宫丽鸿,李楠,等.稳斑汤辅助治疗对急性冠状动脉综合征痰浊血瘀证患者血浆血栓调节蛋白基因启动子甲基化的影响[J].中医杂志,2016,57(2):140-144.
[38]吴瑞华,蔡少杭.胸痹片对痰瘀互阻型不稳定性心绞痛血浆同型半胱氨酸的影响[J].内蒙古中医药,2012,31(8):5-7.
[39]周利军,张旭力,吕俊,等.银丹心脑通软胶囊治疗痰瘀阻滞型冠心病心绞痛[J].中西医结合心脑血管病杂志,2013,11(1):17-18.
[40]王家良.临床流行病学:临床科研设计、测量与评价[M].上海:上海科学技术出版社,2009:158.
[41]刘建平.循证中医药临床研究方法[M].北京:人民卫生出版社,2009:27.
[42]Schulz KF,Altman DG,Moher D.CONSORT 2010 Statement:updated guidelines for reporting parallel group randomised trials[J].BMC Med,2010,8(1):18.
[43]刘建平.临床试验样本含量的计算[J].中国中西医结合杂志,2003,23(7):536-538.
[44]刘建平.定量与定性研究方法相结合的中医临床疗效评价模式[J].中国中西医结合杂志,2011,31(5):581-585.
[45]国家食品药品监督管理局.药物临床试验质量管理规范[J].中药研究与信息,2004,6(3):8-19.
[2]中华人民共和国卫生部.中药新药研究指导原则[M].北京:中国医药科出版社,2002:6-73.
[3]The Cochrane Collaboration.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0(updated March 2011)[S/OL].Editors:Julian PT Higgins and Sally Green.http://www.cochrane.org/.htm.
[4]万洪峰,杨晓卿.泄浊化瘀方治疗痰瘀互结证冠心病的疗效观察[J].大家健康:学术版,2016,10(8):138-139.
[5]任得志,张军茹,申仙利.丹蒌片治疗痰瘀互结型冠心病不稳定型心绞痛的临床观察[J].中西医结合心脑血管病杂志,2014,12(8):1022-1023.
[6]何欣,何立人.瓜蒌薤白养心汤治疗痰瘀互结型冠心病心绞痛临床观察[J].四川中医,2015,33(12):113-116.
[7]刘祖印.通络化痰汤治疗冠心病心绞痛痰瘀互结证的临床分析[J].医学信息,2015,28(46):345.
[8]周占青.薤白通脉汤联合西药治疗冠心病不稳定型心绞痛(痰瘀互结)随机平行对照研究[J].实用中医内科杂志,2015,29(7):110-112.
[9]庞立健,朱凌云,南明花,等.通脉化浊汤治疗痰瘀互结型冠心病心绞痛患者临床疗效评价[J].中华中医药学刊,2013,31(9):1875-1877.
[10]张奎,徐卫东.通络化痰汤治疗冠心病心绞痛痰瘀互结证疗效观察[J].中医药导报,2013,19(12):140-141.
[11]张海文.瓜蒌薤白半夏汤加味治疗冠心病心绞痛痰瘀互结型42例[J].光明中医,2015,30(11):2439-2441.
[12]易慧明.中西医结合治疗痰瘀互结型冠心病稳定型心绞痛的临床分析[J].大家健康旬刊,2014,8(23):93-94.
[13]李防栋,杨学信.心痛灵汤治疗冠心病心绞痛毒热痰瘀互结证疗效观察[J].医药前沿,2015,5(28):330-331.
[14]王宁宁,洛晶,刘超峰.菖琥温胆汤联合β受体阻滞剂治疗冠心病室性早搏(痰瘀互结证)的临床观察[J].现代中医药,2012,32(2):19-20.
[15]王长建,马秀明,王竹风,等.瓜蒌薤白半夏汤合血府逐瘀汤加减治疗痰瘀互结型胸痹心痛32例临床观察[J].新中医,2013(8):12-14.
[16]田丹枫,司国民,彭敏.加味瓜蒌薤白半夏汤治疗冠心病经皮冠状动脉介入术后再发心绞痛痰瘀互结证的临床研究[J].河北中医,2016,38(9):1361-1364.
[17]范虹,安静,刘超峰,等.丹曲方治疗冠心病心绞痛痰瘀毒互结证疗效观察[J].陕西中医,2014(8):973-975.
[18]辜大为.中西医结合治疗阳虚痰瘀互结型冠心病心绞痛49例临床观察[J].中医药导报,2008,14(3):17-18.
[19]周菁,张倩,张焱.白玉参景脉通汤联合常规西药对痰瘀互阻型冠心病患者脂联素水平的影响[J].上海中医药杂志,2016,50(11):42-45.
[20]李淑君,范金茹.柴蒌桃仁汤治疗稳定型心绞痛痰瘀痹阻证的临床研究[J].中医药导报,2010,16(4):19-21.
[21]谭建义.丹蒌片联合西药治疗痰瘀互阻型冠心病心绞痛随机平行对照研究[J].实用中医内科杂志,2013,27(13):20-21.
[22]周敏军.丹蒌片治疗痰瘀互阻型冠心病心绞痛患者70例临床疗效观察[J].中国民族民间医药,2013,22(18):98.
[23]薛振怀,钟伟,程娟.导痰祛瘀汤联合西药治疗痰浊瘀阻型糖尿病合并冠心病随机平行对照研究[J].实用中医内科杂志,2015,29(9):121-123.
[24]谢玉霞,晋卫军,程璐,等.瓜蒌皮注射液联合西药治疗冠心病心绞痛(痰瘀互阻证)合并心衰患者的临床研究[J].实用中西医结合临床,2014,14(7):16-17.
[25]周旭.瓜蒌薤白半夏汤合丹参饮在痰瘀互阻型胸痹治疗中的应用分析[J].中国实用医药,2016,11(29):203-204.
[26]满军.瓜蒌薤白半夏汤合丹参治疗痰阻血瘀型胸痹心痛38例观察[J].中医药临床杂志,2014,26(9):892-893.
[27]王士兵.瓜蒌薤白半夏汤合桃红四物汤联合西药治疗痰阻血瘀型胸痹随机平行对照研究[J].实用中医内科杂志,2016,30(7):52-54.
[28]韩秀芬,韩首章.冠脉通联合西药治疗痰瘀痹阻冠心病心绞痛随机平行对照研究[J].实用中医内科杂志,2016,30(8):66-68.
[29]杨新.冠心通舒汤配合西药治疗痰阻血瘀型胸痹75例[J].实用中医内科杂志,2012,26(1):56-57.
[30]刘宁,姚福梅,李勇,等.化痰祛瘀法对痰浊瘀阻型急性冠脉综合征患者血小板活化功能影响的研究[J].中国实用医药,2010,5(9):9-10.
[31]陈翊,缪灿铭.化痰通络法改善痰瘀阻络型急性冠脉综合征症状及CRP水平[J].光明中医,2008,23(12):1891-1893.
[32]秦玖刚.豁痰通痹汤联合西药治疗痰瘀互阻型胸痹的临床观察[J].中医临床研究,2016,8(20):73-74.
[33]贾秀丽,刘洁,刘华恩.降浊通脉汤治疗痰瘀痹阻型冠心病心绞痛60例[J].河南中医,2007,27(8):28-30.
[34]刘婷,肖振东,李培培.理气化痰祛瘀法治疗冠心病合并高脂血症(痰瘀互阻证)45例[J].中国实验方剂学杂志,2014,20(8):221-225.
[35]杨建波,李鹏,蒋华,等.通瘀化痰法治疗痰瘀互阻证心衰患者的临床研究[J].新疆医科大学学报,2011,34(7):669-673.
[36]杨晓利,周鹏飞,方居正.温胆汤加味联合西药治疗痰瘀痹阻型冠心病30例[J].中医研究,2017,30(2):29-31.
[37]程修平,宫丽鸿,李楠,等.稳斑汤辅助治疗对急性冠状动脉综合征痰浊血瘀证患者血浆血栓调节蛋白基因启动子甲基化的影响[J].中医杂志,2016,57(2):140-144.
[38]吴瑞华,蔡少杭.胸痹片对痰瘀互阻型不稳定性心绞痛血浆同型半胱氨酸的影响[J].内蒙古中医药,2012,31(8):5-7.
[39]周利军,张旭力,吕俊,等.银丹心脑通软胶囊治疗痰瘀阻滞型冠心病心绞痛[J].中西医结合心脑血管病杂志,2013,11(1):17-18.
[40]王家良.临床流行病学:临床科研设计、测量与评价[M].上海:上海科学技术出版社,2009:158.
[41]刘建平.循证中医药临床研究方法[M].北京:人民卫生出版社,2009:27.
[42]Schulz KF,Altman DG,Moher D.CONSORT 2010 Statement:updated guidelines for reporting parallel group randomised trials[J].BMC Med,2010,8(1):18.
[43]刘建平.临床试验样本含量的计算[J].中国中西医结合杂志,2003,23(7):536-538.
[44]刘建平.定量与定性研究方法相结合的中医临床疗效评价模式[J].中国中西医结合杂志,2011,31(5):581-585.
[45]国家食品药品监督管理局.药物临床试验质量管理规范[J].中药研究与信息,2004,6(3):8-19.